PulmonologyNews.net

Pulmonology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

The double blind, randomised and placebo-controlled IMPULSIS trials, involving 1,066 patients across 24 countries, evaluated the effect of oral Nintedanib 150 mg twice daily, on the annual rate of dec ...


The ACLIFORM/COPD study has assessed the efficacy and safety of two doses of twice-daily ( BID ) Aclidinium bromide / Formoterol fumarate fixed-dose combination ( FDC ) in patients with moderate-to-se ...


QVA149 ( Ultibro Breezhaler ), a novel, once-daily dual bronchodilator containing the long-acting beta2-agonist, Indacaterol and long-acting muscarinic antagonist Glycopyrronium, improves lung functio ...


COPD exacerbations are linked to a rapid decline in lung function and increased mortality. QVA149 ( Ultibro Breezhaler ) is a once-daily dual bronchodilator with a fixed-dose combination of long-actin ...


Results from two phase III studies were presented. They have shown that patients with chronic obstructive pulmonary disease ( COPD ) who received the anticholinergic, Incruse Ellipta ( Umeclidinium 62 ...


Fluticasone furoate / Vilanterol ( FF/VI; Relvar Ellipta ) is an inhaled corticosteroid / long-acting beta2-agonist ( ICS / LABA ), recently approved as once-daily maintenance therapy for COPD. Rese ...


Glycopyrronium ( Seebri Breezhaler ) is a once daily long-acting muscarinic antagonist that is approved for maintenance treatment of COPD ( chronic obstructive pulmonary disease ). This post-hoc poole ...


In patients with symptomatic asthma receiving ICS or ICS+LABA, phase III studies have demonstrated improved lung function with Tiotropium ( Spiriva ) Respimat, a once-daily long-acting anticholinergic ...


Although yoga is frequently used by patients with asthma, its efficacy in alleviating asthma remains unclear. A study has systematically assessed the available data on efficacy and safety of yoga in ...


Two once-daily long-acting muscarinic antagonists ( LAMAs ) are currently available for the treatment of chronic obstructive pulmonary disease ( COPD ), Tiotropium ( Spiriva ) and Glycopyrronium ( See ...


There is controversy regarding the impact of chronic obstructive pulmonary disease ( COPD ) in clinical outcomes in elderly patients with pneumonia. Comorbidities such as cardiovascular disease have ...


Dual bronchodilation with a long-acting beta2-agonist ( LABA ) and long-acting muscarinic antagonist ( LAMA ) is recommended for patients with a high symptomatic burden and/or risk of exacerbations ( ...


Combination long-acting bronchodilator therapy may be more effective than long-acting bronchodilator monotherapy in chronic obstructive pulmonary disease ( COPD ). The aim of a study was to compare ...


In mild asthma exercise-induced bronchoconstriction is usually treated with inhaled short-acting beta2-agonists ( SABAs ) on demand. The hypothesis was that a combination of Budesonide and Formoter ...


Chronic obstructive pulmonary disease ( COPD ) is characterized by persistent airflow limitation caused by bronchial alterations, small airways disease and parenchymal destruction. In patients with CO ...